MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited

Eur J Endocrinol. 2018 Jul;179(1):R19-R29. doi: 10.1530/EJE-17-0990. Epub 2018 Apr 19.

Abstract

The syndrome of primary aldosteronism (PA) is characterized by hypertension with excessive, autonomous aldosterone production and is usually caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. The diagnostic workup of PA is a sequence of three phases comprising screening tests, confirmatory tests and the differentiation of unilateral from bilateral forms. The latter step is necessary to determine the optimal treatment approach of unilateral laparoscopic adrenalectomy (for patients with unilateral PA) or medical treatment with a mineralocorticoid receptor antagonist (for patients with bilateral PA). Since the publication of the revised Endocrine Society guideline 2016, a number of key studies have been published. They challenge the recommendations of the guideline in some areas and confirm current practice in others. Herein, we present the recent developments and current approaches to the medical management of PA.

Publication types

  • Review

MeSH terms

  • Adrenalectomy*
  • Disease Management
  • Endocrinology
  • Humans
  • Hyperaldosteronism / complications
  • Hyperaldosteronism / diagnosis
  • Hyperaldosteronism / genetics
  • Hyperaldosteronism / therapy*
  • Hypertension / etiology
  • Hypertension / therapy*
  • Laparoscopy
  • Mass Screening
  • Mineralocorticoid Receptor Antagonists / therapeutic use*
  • Practice Guidelines as Topic*
  • Societies, Medical

Substances

  • Mineralocorticoid Receptor Antagonists